SEC Company Response from TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686) (TEVA) — May 7, 2007

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686)
Date: May 7, 2007 · CIK: 0000818686 · Accession: 0000899140-07-000901

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 000-16174

Referenced dates: April 23, 2007

Date

May 7, 2007

Author

/s/ Jeffrey S. Hochman

Form

CORRESP

Company

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686)

Letter

Re: Teva Pharmaceutical Industries Limited Form 20-F for the Fiscal Year Ended December 31, 2006 File No. 000-16174 ------------------ Dear Mr. Rosenberg:

[LETTERHEAD OF WILLKIE FARR & GALLAGHER LLP]

VIA EDGAR ---------

May 7, 2007

Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant Division of Corporation Finance

I refer to the letter dated April 23, 2007 from Jim B. Rosenberg to Dan S. Suesskind, Chief Financial Officer of Teva Pharmaceutical Industries Limited, regarding the Teva filing with the Commission referenced above. Teva is actively working on its response to the comment of the Staff raised in the letter and expects to submit its response by the end of the month, if not earlier.

Should any member of the Staff have any questions, please do not hesitate to call me at (212) 728-8592.

Very truly yours,
/s/ Jeffrey S. Hochman

Show Raw Text

<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
                  [LETTERHEAD OF WILLKIE FARR & GALLAGHER LLP]

VIA EDGAR
---------

May 7, 2007

Securities and Exchange Commission 100 F Street, N.E.
Washington, D.C.  20549
Attn:  Jim B. Rosenberg, Senior Assistant Chief Accountant
       Division of Corporation Finance

Re:  Teva Pharmaceutical Industries Limited
     Form 20-F for the Fiscal Year Ended December 31, 2006
     File No. 000-16174
     ------------------
Dear Mr. Rosenberg:

     I refer to the letter dated April 23, 2007 from Jim B. Rosenberg to Dan S.
Suesskind, Chief Financial Officer of Teva Pharmaceutical Industries Limited,
regarding the Teva filing with the Commission referenced above. Teva is actively
working on its response to the comment of the Staff raised in the letter and
expects to submit its response by the end of the month, if not earlier.

     Should any member of the Staff have any questions, please do not hesitate
to call me at (212) 728-8592.

Very truly yours,

/s/ Jeffrey S. Hochman

Jeffrey S. Hochman

cc:   James Peklenk (SEC)
      Dan S. Suesskind (Teva)
      Uzi Karniel (Teva)
      Peter H. Jakes (Willkie Farr)

</TEXT>
</DOCUMENT>

SecProbe.io